Header Camel-IDS

Welcome to our new international investors that has extensive experience in leveraging platform technologies to develop multi-product opportunities.

Ruth Devenyns - CEO


Camel-IDS, founded in 2014 as a spin-off from Vrije Universiteit Brussel (VUB), develops radio-immunotherapeutic drugs for breast cancer patients. Their unique technology platform is based on the unique characteristics of the Camelid immune system and allows fast and specific delivery of therapeutic radiation to cancer cells, while sparing healthy tissues.

Icon entry


Icon location


When ambition meets ambition

The Camel-IDS team has a renowned expertise in radio-immunotherapy and is well positioned to move up to the next level.

This investment clearly fits into our Health & Care strategy and, with a platform portfolio of about 20 companies, underpins our position as one of the most active European investors in the healthcare industry.

Together, we build a leading company

With this financing, which is one of the larger rounds of a European early-stage life sciences company, Camel-IDS will be able to run a phase Ib/II trial with its lead program targeting brain metastatic breast cancer, while further progressing and broadening its preclinical pipeline. We are delighted that we can contribute to this lead program thanks to our expertise through earlier investments in life sciences companies.


Developer of cancer-targeted radiopharmaceuticals